State of Wisconsin Investment Board Purchases New Stake in Aratana Therapeutics, Inc. (PETX)

State of Wisconsin Investment Board purchased a new position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,000 shares of the biopharmaceutical company’s stock, valued at approximately $210,000. State of Wisconsin Investment Board owned 0.08% of Aratana Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Janney Montgomery Scott LLC lifted its holdings in shares of Aratana Therapeutics by 7.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,200 shares during the period. American International Group Inc. lifted its holdings in shares of Aratana Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the period. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Aratana Therapeutics by 17.9% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares during the period. Weiss Multi Strategy Advisers LLC lifted its holdings in shares of Aratana Therapeutics by 8.3% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 5,000 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Aratana Therapeutics by 8.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 65,415 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 5,165 shares during the period. 73.07% of the stock is owned by institutional investors and hedge funds.

Aratana Therapeutics, Inc. (NASDAQ PETX) opened at 6.26 on Friday. The stock has a 50 day moving average price of $5.90 and a 200 day moving average price of $6.18. Aratana Therapeutics, Inc. has a one year low of $4.97 and a one year high of $10.73. The firm’s market cap is $269.19 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. During the same period last year, the company posted $0.61 EPS. The company’s revenue was down 86.4% on a year-over-year basis. Equities research analysts expect that Aratana Therapeutics, Inc. will post ($1.09) EPS for the current year.

Several brokerages have recently issued reports on PETX. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. BidaskClub cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC set a $8.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Lake Street Capital decreased their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $8.25.

TRADEMARK VIOLATION WARNING: “State of Wisconsin Investment Board Purchases New Stake in Aratana Therapeutics, Inc. (PETX)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/09/16/state-of-wisconsin-investment-board-purchases-new-stake-in-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply